Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using small mole...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Oncol
Egile Nagusiak: Golub, Danielle, Iyengar, Nishanth, Dogra, Siddhant, Wong, Taylor, Bready, Devin, Tang, Karen, Modrek, Aram S., Placantonakis, Dimitris G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2019
Gaiak:
Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534082/
https://ncbi.nlm.nih.gov/pubmed/31165048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00417
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak